Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Lorenz Kocheise; Ignazio Piseddu; Joscha Vonderlin; Eric T. Tjwa; Gustav Buescher; Lucy Meunier; Pia Goeggelmann; Francesca Fianchi; Jerome Dumortier; Mar Riveiro Barciela; Tom J. G. Gevers; Benedetta Terziroli Beretta-Piccoli; Maria-Carlota Londono; Sona Frankova; Thomas Roesner; Vincent Joerg; Constantin Schmidt; Fabian Glaser; Jan P. Sutter; Thorben W. Fruendt; Ansgar W. Lohse; Samuel Huber; Johann von Felden; Marcial Sebode; Kornelius Schulze

doi:10.3389/fimmu.2024.1369747

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Lorenz Kocheise^*, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jerome Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londono, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. FruendtAnsgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Abstract

In the published article, there was an error in Table 2. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected Table 2 and its caption appear below. Immune-related adverse events and immunosuppression. No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. #Multiple treatments possible *Treatment for Rheumatoid arthritis. The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original language	English
Article number	1369747
Number of pages	2
Journal	Frontiers in Immunology
Volume	15
DOIs	https://doi.org/10.3389/fimmu.2024.1369747
Publication status	Published - 24 Jan 2024

Keywords

autoimmune disease (AID)
immune checkpoint inhibitors (ICI)
autoimmune liver diseases (AILD)
immune related adverse effects (irAEs)
PD-1/PD-L1 immune checkpoint inhibitors
autoimmune hepatitis (AIH)
primary sclerosing cholangites (PSC)
primary biliary cholangitis (PBC)

Access to Document

10.3389/fimmu.2024.1369747Licence: CC BY

1 Article

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Kocheise, L., Piseddu, I., Vonderlin, J., Tjwa, E. T., Buescher, G., Meunier, L., Goeggelmann, P., Fianchi, F., Dumortier, J., Riveiro Barciela, M., Gevers, T. J. G., Terziroli Beretta-Piccoli, B., Londono, M.-C., Frankova, S., Roesner, T., Joerg, V., Schmidt, C., Glaser, F., Sutter, J. P. & Fruendt, T. W. & 5 others, Lohse, A. W., Huber, S., von Felden, J., Sebode, M. & Schulze, K., 10 Jan 2024, In: Frontiers in Immunology. 14, 9 p., 1326078.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Cite this

Kocheise, L., Piseddu, I., Vonderlin, J., Tjwa, E. T., Buescher, G., Meunier, L., Goeggelmann, P., Fianchi, F., Dumortier, J., Barciela, M. R., Gevers, T. J. G., Beretta-Piccoli, B. T., Londono, M.-C., Frankova, S., Roesner, T., Joerg, V., Schmidt, C., Glaser, F., Sutter, J. P., ... Schulze, K. (2024). Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Frontiers in Immunology, 15, Article 1369747. https://doi.org/10.3389/fimmu.2024.1369747

@article{b16e094e0ed846eea3f6b2beff297e21,

title = "Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease",

abstract = "In the published article, there was an error in Table 2. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected Table 2 and its caption appear below. Immune-related adverse events and immunosuppression. No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. #Multiple treatments possible *Treatment for Rheumatoid arthritis. The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.",

keywords = "autoimmune disease (AID), immune checkpoint inhibitors (ICI), autoimmune liver diseases (AILD), immune related adverse effects (irAEs), PD-1/PD-L1 immune checkpoint inhibitors, autoimmune hepatitis (AIH), primary sclerosing cholangites (PSC), primary biliary cholangitis (PBC)",

author = "Lorenz Kocheise and Ignazio Piseddu and Joscha Vonderlin and Tjwa, {Eric T.} and Gustav Buescher and Lucy Meunier and Pia Goeggelmann and Francesca Fianchi and Jerome Dumortier and Barciela, {Mar Riveiro} and Gevers, {Tom J. G.} and Beretta-Piccoli, {Benedetta Terziroli} and Maria-Carlota Londono and Sona Frankova and Thomas Roesner and Vincent Joerg and Constantin Schmidt and Fabian Glaser and Sutter, {Jan P.} and Fruendt, {Thorben W.} and Lohse, {Ansgar W.} and Samuel Huber and {von Felden}, Johann and Marcial Sebode and Kornelius Schulze",

year = "2024",

month = jan,

day = "24",

doi = "10.3389/fimmu.2024.1369747",

language = "English",

volume = "15",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

}

Kocheise, L, Piseddu, I, Vonderlin, J, Tjwa, ET, Buescher, G, Meunier, L, Goeggelmann, P, Fianchi, F, Dumortier, J, Barciela, MR, Gevers, TJG, Beretta-Piccoli, BT, Londono, M-C, Frankova, S, Roesner, T, Joerg, V, Schmidt, C, Glaser, F, Sutter, JP, Fruendt, TW, Lohse, AW, Huber, S, von Felden, J, Sebode, M & Schulze, K 2024, 'Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease', Frontiers in Immunology, vol. 15, 1369747. https://doi.org/10.3389/fimmu.2024.1369747

TY - JOUR

T1 - Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

AU - Kocheise, Lorenz

AU - Piseddu, Ignazio

AU - Vonderlin, Joscha

AU - Tjwa, Eric T.

AU - Buescher, Gustav

AU - Meunier, Lucy

AU - Goeggelmann, Pia

AU - Fianchi, Francesca

AU - Dumortier, Jerome

AU - Barciela, Mar Riveiro

AU - Gevers, Tom J. G.

AU - Beretta-Piccoli, Benedetta Terziroli

AU - Londono, Maria-Carlota

AU - Frankova, Sona

AU - Roesner, Thomas

AU - Joerg, Vincent

AU - Schmidt, Constantin

AU - Glaser, Fabian

AU - Sutter, Jan P.

AU - Fruendt, Thorben W.

AU - Lohse, Ansgar W.

AU - Huber, Samuel

AU - von Felden, Johann

AU - Sebode, Marcial

AU - Schulze, Kornelius

PY - 2024/1/24

Y1 - 2024/1/24

N2 - In the published article, there was an error in Table 2. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected Table 2 and its caption appear below. Immune-related adverse events and immunosuppression. No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. #Multiple treatments possible *Treatment for Rheumatoid arthritis. The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

AB - In the published article, there was an error in Table 2. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected Table 2 and its caption appear below. Immune-related adverse events and immunosuppression. No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. #Multiple treatments possible *Treatment for Rheumatoid arthritis. The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

KW - autoimmune disease (AID)

KW - immune checkpoint inhibitors (ICI)

KW - autoimmune liver diseases (AILD)

KW - immune related adverse effects (irAEs)

KW - PD-1/PD-L1 immune checkpoint inhibitors

KW - autoimmune hepatitis (AIH)

KW - primary sclerosing cholangites (PSC)

KW - primary biliary cholangitis (PBC)

U2 - 10.3389/fimmu.2024.1369747

DO - 10.3389/fimmu.2024.1369747

M3 - Erratum / corrigendum / retractions

SN - 1664-3224

VL - 15

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 1369747

ER -

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Abstract

Keywords

Access to Document

Fingerprint

Research output

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Cite this